Buying stocks set to benefit from big global growth themes can be a lucrative strategy. Such trends can potentially drive market-beating returns for years.
One area seeing strong growth today is the global sports nutrition, health, and wellness industry. According to market researcher Euromonitor, this will reach £279bn by the end of 2028, growing at annualised rate of 8.1%.
Here are two stocks that look primed to continue benefiting from this trend for years to come.
Gym Group
UK gym memberships are now at record levels. And one beneficiary is Gym Group (LSE:GYM), which operated 260 low-cost gyms across the UK at the end of 2025.
The stock is up 35% year to date. But I still like it moving forward, with Gym Group on track to open 20 more sites this year, and 75 over the next three years (up from 50 previously).
Last year, revenue ticked up 8% to £245m, with average revenue per member per month growing 4% to £21.60. And adjusted pre-tax profit surged 194% to £10.6m as the firm continues to improve profitability following the pandemic.
An historic milestone has also been reached, with its membership reaching around 1m people today. However, this remains a very competitive market, with plenty to chose from when it comes to gyms and fitness centres.
On the other hand, this is a growing market. And surveys show that Gen Z now classifies health and fitness as their number one or two priority when it comes to discretionary spending. So the low-cost gym operator is arguably insulated from the ongoing cost-of-living pressures.
Meanwhile, management sees GLP-1 weight-loss drugs as a powerful growth support. That’s because users are gaining the confidence to go to the gym after losing weight, while strength training protects muscle mass during the treatment period.
The stock isn’t conventionally cheap at 37 times forward earnings, but profits are set to grow by double digits as the group scales up. All nine analysts following the stock rate it a Buy.
Finally, the share price is still 33% lower than before the pandemic.
Hims & Hers
My next pick is a little more left field: Hims & Hers Health (NYSE:HIMS).
This is the digital consumer health platform that prescribes and sells affordable treatments for hair loss, hormone optimisation, sexual health, and weight loss (including a strategic partnership with Novo Nordisk to sell Wegovy).
However, the company is expanding its diagnostics offerings (such as whole-body lab testing) and entering new categories like longevity and peptides. It recently added eight new brand partners for its paying members, spanning nutrition, fitness, glucose monitoring, and meal delivery (HelloFresh).
In 2025, the firm reported revenue of $2.35bn, up 59% year on year, and adjusted EBITDA of $318m. However, by 2030, it’s targeting at least $6.5bn and $1.3bn respectively, with the recent acquisition of Eucalyptus expanding its presence to Australia and parts of Europe.
The future of health isn’t inside of a doctor’s office. It will be integrated into the rhythm of your daily life, anticipating issues before you even see them.
CEO Andrew Dudum
Again, competition is a risk here (especially from Amazon), as is regulatory complexity in some overseas markets. But with the stock down 50% from its 52-week high, I reckon it’s worth a look today.
Should you invest £5,000 in Gym Group Plc right now?
When investing expert Mark Rogers and his team have a stock tip, it can pay to listen. After all, the flagship Twelfth Magpie Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.
And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Gym Group Plc made the list?
Ben McPoland owns shares in Hims & Hers.
